Wells Fargo & Company Forecasts Strong Price Appreciation for Agilon Health (NYSE:AGL) Stock

Agilon Health (NYSE:AGL) had its price objective increased by investment analysts at Wells Fargo & Company from $146.00 to $170.00 in a report released on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 55.11% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Benchmark reiterated a “buy” rating and issued a $140.00 price objective (up from $95.00) on shares of Agilon Health in a report on Thursday, August 6th. Barclays set a $111.00 target price on Agilon Health and gave the stock an “equal weight” rating in a research report on Thursday, August 6th. Citigroup upgraded shares of Agilon Health from a “sell” rating to a “neutral” rating and upped their target price for the company from $105.00 to $115.00 in a research note on Monday, August 10th. JPMorgan Chase & Co. raised their price target on shares of Agilon Health from $31.00 to $85.00 and gave the company an “underweight” rating in a report on Monday, August 24th. Finally, Royal Bank Of Canada set a $125.00 price target on shares of Agilon Health in a research note on Tuesday, September 15th. Seven research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $107.38.

Agilon Health Stock Down 0.6%

AGL traded down $0.70 during trading on Friday, hitting $109.60. 26,961 shares of the company’s stock traded hands, compared to its average volume of 316,635. The company’s 50 day simple moving average is $90.11 and its two-hundred day simple moving average is $68.51. The company has a current ratio of 1.13, a quick ratio of 1.13 and a debt-to-equity ratio of 0.06. Agilon Health has a 12-month low of $7.48 and a 12-month high of $133.04. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -19.75 and a beta of 3.10.

Agilon Health (NYSE:AGL) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $1.97 earnings per share for the quarter, topping the consensus estimate of ($1.23) by $3.20. The firm had revenue of $1.52 billion during the quarter, compared to analysts’ expectations of $1.46 billion. Agilon Health had a negative return on equity of 51.97% and a negative net margin of 1.45%. Analysts predict that Agilon Health will post -2.90 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agilon Health

Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp purchased a new position in shares of Agilon Health in the 2nd quarter worth $30,024,000. Rubicon Founders LLC purchased a new stake in Agilon Health during the second quarter valued at $11,290,448. Tidal Investments LLC purchased a new stake in Agilon Health during the second quarter valued at $1,405,000. Ellsworth Advisors LLC bought a new position in Agilon Health in the third quarter valued at about $809,000. Finally, Great Lakes Advisors LLC bought a new position in Agilon Health in the second quarter valued at about $702,000.

About Agilon Health

Agilon Health is a U.S. healthcare company that partners with primary care physicians to provide care for patients enrolled in Medicare Advantage plans. Its model is designed to help physician groups move from traditional fee-for-service care toward value-based care, in which providers are rewarded for improving patients’ health and coordinating their care. The company provides participating physician groups with clinical, operational, technology and administrative support, along with resources to manage patient populations and coordinate care across local healthcare networks.